Next-generation probiotics - do they open new therapeutic strategies for cancer patients?

ABSTRACT: Gut microbiota and its association with cancer development/treatment has been intensively studied during the past several years. Currently, there is a growing interest toward next-generation probiotics (NGPs) as therapeutic agents that alter gut microbiota and impact on cancer development. In the present review we focus on three emerging NGPs, namely Faecalibacterium prausnitzii, Akkermansia muciniphila, and Bacteroides fragilis as their presence in the digestive tract can have an impact on cancer incidence. These NGPs enhance gastrointestinal immunity, maintain intestinal barrier integrity, produce beneficial metabolites, act against pathogens, improve immunotherapy efficacy, and reduce complications associated with chemotherapy and radiotherapy. Notably, the use of NGPs in

SUBMITTER: Kazmierczak-Siedlecka K 

PROVIDER: S-EPMC8855854 | biostudies-literature | 2022 Jan-Dec

REPOSITORIES: biostudies-literature